Cargando…

Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematologic malignancies characterized by clonal hematopoiesis, one or more cytopenias such as anemia, neutropenia, or thrombocytopenia, abnormal cellular maturation, and a high risk of progression to acute myeloid leukemia. The bone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bains, Amanpreet Kaur, Behrens Wu, Lena, Rivière, Jennifer, Rother, Sandra, Magno, Valentina, Friedrichs, Jens, Werner, Carsten, Bornhäuser, Martin, Götze, Katharina S., Cross, Michael, Platzbecker, Uwe, Wobus, Manja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492883/ https://www.ncbi.nlm.nih.gov/pubmed/36158640 http://dx.doi.org/10.3389/fonc.2022.961473

Ejemplares similares

P705: AZACYTIDINE THERAPY REVERTS MDS-ASSOCIATED CHANGES IN MSC-DERIVED EXTRACELLULAR MATRIX
por: Bains, Amanpreet, et al.
Publicado: (2023)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway
por: Balaian, Ekaterina, et al.
Publicado: (2018)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

Editorial: Deciphering the bone marrow microenvironment in hematologic malignancies
por: Wobus, Manja, et al.
Publicado: (2023)

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells
por: Wobus, Manja, et al.
Publicado: (2021)

Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes
por: Götze, Katharina S., et al.
Publicado: (2018)

Machine learning assisted real-time deformability cytometry of CD34+ cells allows to identify patients with myelodysplastic syndromes
por: Herbig, Maik, et al.
Publicado: (2022)

Human Bone Marrow Stromal Cells: A Reliable, Challenging Tool for In Vitro Osteogenesis and Bone Tissue Engineering Approaches
por: Hempel, Ute, et al.
Publicado: (2016)

Mesenchymal Stromal Cell-Derived Extracellular Vesicles Modulate Hematopoietic Stem and Progenitor Cell Viability and the Expression of Cell Cycle Regulators in an Age-dependent Manner
por: Fichtel, Pascal, et al.
Publicado: (2022)

Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update
por: Müller, Luise, et al.
Publicado: (2021)

Mesenchymal stromal cell-associated migrasomes: a new source of chemoattractant for cells of hematopoietic origin
por: Deniz, Ilker A., et al.
Publicado: (2023)

Facing the challenge: Novel treatment options for patients with myelodysplastic syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Current challenges and unmet medical needs in myelodysplastic syndromes
por: Platzbecker, Uwe, et al.
Publicado: (2021)

Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease
por: Krüger, Thomas, et al.
Publicado: (2022)

Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome
por: Radujkovic, Aleksandar, et al.
Publicado: (2015)

Spheroid Culture of Mesenchymal Stromal Cells Results in Morphorheological Properties Appropriate for Improved Microcirculation
por: Tietze, Stefanie, et al.
Publicado: (2019)

Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2019)

Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma
por: Choi, Hayoung, et al.
Publicado: (2020)

Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo
por: Jann, Johann-Christoph, et al.
Publicado: (2021)

Bone marrow niche-mimetics modulate HSPC function via integrin signaling
por: Kräter, Martin, et al.
Publicado: (2017)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape
por: Schwind, Sebastian, et al.
Publicado: (2021)

OXPHOS Supercomplexes as a Hallmark of the Mitochondrial Phenotype of Adipogenic Differentiated Human MSCs
por: Hofmann, Andreas D., et al.
Publicado: (2012)

Bone marrow niches in myelodysplastic syndromes
por: Tosato, Giovanna, et al.
Publicado: (2021)

Sonic Hedgehog Produced by Bone Marrow-Derived Mesenchymal Stromal Cells Supports Cell Survival in Myelodysplastic Syndrome
por: Zou, Jixue, et al.
Publicado: (2015)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Glycosaminoglycans and Glycosaminoglycan Mimetics in Cancer and Inflammation
por: Morla, Shravan
Publicado: (2019)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts
por: Kasprzak, A., et al.
Publicado: (2022)

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update
por: Jain, Akriti G., et al.
Publicado: (2022)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Phenotypic, Morphological and Adhesive Differences of Human Hematopoietic Progenitor Cells Cultured on Murine versus Human Mesenchymal Stromal Cells
por: Reichert, Doreen, et al.
Publicado: (2015)

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
por: Oelschlaegel, U, et al.
Publicado: (2016)

Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression
por: Weickert, Marie-Theresa, et al.
Publicado: (2021)

The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
por: Park, Sophie, et al.
Publicado: (2019)

Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
por: Park, Sophie, et al.
Publicado: (2019)

The growth of myelodysplastic bone marrow in long-term cultures.
por: Borbenyi, Z., et al.
Publicado: (1987)

Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study
por: Mittelman, Moshe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_phrr2u687qjibectgpvakr0ep5